Geron rallies after FDA lifts trial hold
NEW YORK |
NEW YORK (Reuters) - Shares of Geron Corp (GERN.O) surged 17.5 percent to $5.64 in premarket trading on Friday after it said the Food and Drug Administration had lifted a hold on an early-stage trial of the company's embryonic stem cell-based therapy.
(Reporting by Ryan Vlastelica; Editing by Theodore d'Afflisio)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters